You are here

Development of an ELISA for Pro-Cathepsin D.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 22108
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1993
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
80 Rogers Street
Cambridge, MA 02142
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 James R. Zabrecky
 (617) 492-7289
Business Contact
Phone: () -
Research Institution
N/A
Abstract

There is mounting evidence that the over-production of the lysosomal enzyme, Cathepsin D, can be a useful prognostic marker in breast cancer. Cathepsin D is synthesized as a 52 kDa precursor (pro-CD)) that is processed into the active mature form made up of 34k and 14k subunits. Although pro-CD is the form that is abnormally secreted by tumor cells, currently available assays measure the mature form and thus normal levels of endogenous enzyme may confound the interpretation of test results. An assay that is specific for the 52 kDa pro-form could prove to be a more reliable prognostic indicator for breast as well as other types of cancer. The goal is to generate monoclonal and polyclonal antibodies which specifically recognize epitopes in the pro-sequence of cathepsin D. Two peptides derived from this sequence will be synthesized and used to immunize mice and rabbits. Resulting antibodies will be used together with ones that already exist to format an ELISA for the quantitation of pro-CD. The assay will be used to evaluate a small number of sera and tumor samples from breast cancer patients.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government